Invention Grant
- Patent Title: Dual function fibroblast growth factor 21 proteins
- Patent Title (中): 双功能成纤维细胞生长因子21蛋白
-
Application No.: US13626207Application Date: 2012-09-25
-
Publication No.: US09458214B2Publication Date: 2016-10-04
- Inventor: Brian R. Boettcher , Shari L. Caplan , Douglas S. Daniels , Norio Hamamatsu , Stuart Licht , Stephen Craig Weldon , Susan E. Cellitti , Bernhard Hubert Geierstranger , Andreas Loew
- Applicant: NOVARTIS AG , IRM LLC
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent Hong-Van M. Le
- Main IPC: A61K38/18
- IPC: A61K38/18 ; A61K38/26 ; C07K14/50 ; C07K14/605
Abstract:
The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
Public/Granted literature
- US20130129724A1 DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS Public/Granted day:2013-05-23
Information query
IPC分类:
